Four-Drug Combo for HCV Shows Early Promise
(MedPage Today) — Combining traditional therapy for HCV infection with the newly approved drug telaprevir (Incivek) and an investigational oral HCV polymerase inhibitor boosted 24-week complete virologic response rates to 90% in a phase II study, the drugs’ manufacturer said.
Article printed from Gastroenterology Education and CPD for trainees and specialists: https://www.gastrotraining.com